Transmembrane receptors

Detmar Logistics Reserves 300 Hyliion Hypertruck ERX™ Units, Expanding Fleet Electrification Collaboration

Retrieved on: 
Monday, August 2, 2021
Trucking, Automotive, General Automotive, Transport, Automotive Manufacturing, Alternative energy, Manufacturing, Energy, Logistics, Supply chain management, Fleet management, Transmembrane receptors, ER-X, ERx, Draft:Hyliion

(NYSE: HYLN) (Hyliion), a leader in electrified powertrain solutions for Class 8 semi-trucks, today announced that Detmar Logistics LLC has executed a reservation agreement covering 300 Hypertruck ERX systems.

Key Points: 
  • (NYSE: HYLN) (Hyliion), a leader in electrified powertrain solutions for Class 8 semi-trucks, today announced that Detmar Logistics LLC has executed a reservation agreement covering 300 Hypertruck ERX systems.
  • Detmar is actively expanding their fleet operations and sees Hyliions Hypertruck ERX as an enabling technology to accelerate their growth.
  • Hyliion will begin showcasing the Hypertruck ERX demonstration units to the Detmar team in late 2021, with trials running in 2022.
  • The purchase and sale of the 300 Hypertruck ERX units is subject to the execution of a final agreement between Hyliion and Detmar.

aTyr Pharma Presents Poster Demonstrating Functional Selectivity of Second Anti-NRP2 Antibody

Retrieved on: 
Thursday, June 10, 2021
Integral membrane proteins, Membrane proteins, Transmembrane proteins, Single-pass transmembrane proteins, Transmembrane receptors, Neuropilin 2, Neuropilin, Semaphorin, E-selectin, aTyr Pharma

The poster presents preclinical findings demonstrating in vitro and in vivo proof-of-concept that the anti-Neuropilin-2 (NRP2) antibody, aNRP2-14, is a high affinity, selective blocker of the Semaphorin 3F/NRP2 interaction.

Key Points: 
  • The poster presents preclinical findings demonstrating in vitro and in vivo proof-of-concept that the anti-Neuropilin-2 (NRP2) antibody, aNRP2-14, is a high affinity, selective blocker of the Semaphorin 3F/NRP2 interaction.
  • Class 3 Semaphorins are an important set of NRP2 ligands, with recent data implicating their role in sustaining chronic inflammation.
  • Details of the abstract and poster presentation are as follows:
    The poster is also available on the aTyr website.
  • aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways.

Saniona to Present Preclinical Data on SAN711 at the 7th Congress of the European Academy of Neurology

Retrieved on: 
Tuesday, June 8, 2021
Branches of biology, Neurochemistry, Gába, Transmembrane receptors, GABAA receptor, GABA receptor, gamma-Aminobutyric acid, Allosteric regulation, Allosteric modulator

SAN711 is a first-in-class positive allosteric modulator of GABA-A 3 that was designed using Sanionas ion channel drug discovery engine.

Key Points: 
  • SAN711 is a first-in-class positive allosteric modulator of GABA-A 3 that was designed using Sanionas ion channel drug discovery engine.
  • While existing molecules target all GABA-A receptors indiscriminately, SAN711 selectively enhances the effects of GABA-A on 3 containing receptors.
  • Saniona also plans to continue to share its data on SAN711 and other preclinical programs in additional scientific and investor forums.
  • Saniona expects to begin a Phase 1 study of SAN711 in healthy volunteers in mid-2021, with data expected in early 2022.

GBT Announces Participation in Upcoming Investor Conferences

Retrieved on: 
Thursday, July 30, 2020
Proteins, Branches of biology, Life sciences, Selectins, Health in Africa, Hematopathology, RTT, Sickle cell disease, Transmembrane receptors, Scd, P-selectin, Genuity

ET; and

Key Points: 
  • ET; and
    Canaccord Genuity 40th Annual Growth Virtual Conference on August 13 at 1:30 p.m.
  • Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities.
  • Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder.
  • GBT is also advancing its pipeline program in SCD with inclacumab, a p-selectin inhibitor in development to address pain crises associated with the disease.

New Efficacy and Biomarker Data From Rivipansel Phase 3 RESET Trial to Be Presented at Sickle Cell Meeting

Retrieved on: 
Friday, June 12, 2020
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical trials, Other Health, Proteins, Branches of biology, Membrane proteins, Selectins, Biomarkers, Transmembrane receptors, Glycoproteins, E-selectin, P-selectin, Sickle Cell Disease (SCD) and VOC, Rivipansel, GMI-1687, GlycoMimetics, Inc.

This analysis and new biomarker data will be presented at the September meeting of the Foundation for Sickle Cell Disease Research (FSCDR).

Key Points: 
  • This analysis and new biomarker data will be presented at the September meeting of the Foundation for Sickle Cell Disease Research (FSCDR).
  • Furthermore, patients treated with rivipansel showed a statistically significant reduction in soluble E-selectin, a biomarker indicating that the drug had the intended biological effect.
  • Data from the RESET trial additionally demonstrate a safety profile for rivipansel comparable to the placebo.
  • In addition, the biomarker data showing reductions in soluble E-selectin indicates that rivipansel is hitting its intended biological target.

Activin Receptor Type 1 - Pipeline Review, H1 2020 - ResearchAndMarkets.com

Retrieved on: 
Monday, April 6, 2020
Pharmaceutical, Health, Clinical trials, Proteins, Branches of biology, Protein structure, Single-pass transmembrane proteins, Activin receptor, Activin and inhibin, Transmembrane receptors, ACVR1, Receptor protein serine/threonine kinase, Transforming growth factor beta, Targeted therapy, ACVR2B

The "Activin Receptor Type 1 - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Activin Receptor Type 1 - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • According to the report, the pipeline Target constitutes close to 14 molecules.
  • This report outlays comprehensive information on the Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
  • It also reviews key players involved in Activin Receptor Type 1 targeted therapeutics development with respective active and dormant or discontinued projects.

Global Activin Receptor Type 1 Pipeline & Therapeutic Landscape Assessment, 2020

Retrieved on: 
Wednesday, April 1, 2020
Proteins, Branches of biology, Protein structure, Single-pass transmembrane proteins, Activin receptor, Activin and inhibin, Transmembrane receptors, ACVR1, Receptor protein serine/threonine kinase, TGF beta receptors, Transforming growth factor beta, ACVR2B

DUBLIN, April 1, 2020 /PRNewswire/ -- The "Activin Receptor Type 1 - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, April 1, 2020 /PRNewswire/ -- The "Activin Receptor Type 1 - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • According to the report, the pipeline Target constitutes close to 14 molecules.
  • This report outlays comprehensive information on the Activin Receptor Type 1 (Activin Receptor Like Kinase 2 or Serine/Threonine Protein Kinase Receptor R1 or TGF B Superfamily Receptor Type I or ALK2 or ACVR1 or EC 2.7.11.30) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
  • It also reviews key players involved in Activin Receptor Type 1 targeted therapeutics development with respective active and dormant or discontinued projects.

VCAM-1 (Vascular Cell Adhesion Molecule-1) Gene Expression Inhibitor - Pipeline Insight, 2019 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 22, 2019
Health, Genetics, Proteins, Branches of biology, SIGLEC, VCAM-1, Membrane proteins, Cell adhesion, Protein domains, Transmembrane receptors, Single-pass transmembrane proteins, IgSF CAM, Zaurategrast

The "VCAM-1 (vascular cell adhesion molecule-1) gene expression inhibitor -Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "VCAM-1 (vascular cell adhesion molecule-1) gene expression inhibitor -Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across VCAM-1 (vascular cell adhesion molecule-1) gene expression inhibitor development.
  • The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
  • The report assesses the active VCAM-1 (vascular cell adhesion molecule-1) gene expression inhibitor pipeline products by developmental stage, product type, molecule type, and administration route.

GABA-Receptor Modulation in the Treatment of Neurological Diseases

Retrieved on: 
Tuesday, December 4, 2018
Neuroscience, Biology, Neurochemistry, Neurotransmitters, G protein-coupled receptors, Transmembrane receptors, Ion channels, Gába, gamma-Aminobutyric acid, GABA receptor, Inhibitory postsynaptic potential, GABAA receptor

Neurons transmit information in the brain and communicate with each other through surface molecules called receptors.

Key Points: 
  • Neurons transmit information in the brain and communicate with each other through surface molecules called receptors.
  • The main inhibitory receptor in the mammalian brain, GABA-A-receptors (GABAARs), are activated by the neurotransmitter GABA, which is released from neurons.
  • Thus, modulation of the signaling pathways that regulate s-GABARs activity may provide new and safer treatments for epilepsy.
  • Dr. Sylantyev said that "GABA-independent modulation of spontaneously opening GABA-receptors is a perspective direction for the search for new anti-epileptic drugs free from common side effects."